HCW Biologics Inc. (NASDAQ:HCWB) Short Interest Up 905.4% in February

HCW Biologics Inc. (NASDAQ:HCWB) was the recipient of a large growth in short interest in the month of February. As of February 15th, there was short interest totalling 835,500 shares, a growth of 905.4% from the January 31st total of 83,100 shares. Approximately 3.6% of the shares of the stock are short sold. Based on an average trading volume of 6,100,000 shares, the short-interest ratio is currently 0.1 days.

HCW Biologics Price Performance

HCWB traded up $0.01 on Thursday, reaching $0.38. 83,568 shares of the company’s stock were exchanged, compared to its average volume of 9,739,002. The stock has a market cap of $16.70 million, a PE ratio of -0.38 and a beta of 0.81. HCW Biologics has a twelve month low of $0.21 and a twelve month high of $2.52. The stock’s fifty day moving average price is $0.39 and its 200-day moving average price is $0.47.

About HCW Biologics

HCW Biologics Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases.